$SNPX
Synaptogenix, Inc.

2021 Form 10-K Financial Statement

#000141057822000610 Filed on March 29, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.282M $1.551M $8.087M
YoY Change 2.41% -35.91% -26.29%
% of Gross Profit
Research & Development $4.336M $1.410M $3.069M
YoY Change 41.3% 422.22% -32.41%
% of Gross Profit
Depreciation & Amortization $4.966K $1.230K $4.872K
YoY Change 1.93% 10.98%
% of Gross Profit
Operating Expenses $12.62M $2.964M $11.16M
YoY Change 13.1% 10.19% -28.09%
Operating Profit
YoY Change
Interest Expense $7.110K -$90.00 $153.2K
YoY Change -95.36% -100.11% -59.54%
% of Operating Profit
Other Income/Expense, Net $7.110K -$1.547M
YoY Change -100.46%
Pretax Income -$12.61M -$2.964M -$12.70M
YoY Change -0.72% 13.57% -16.07%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.61M -$1.530M -$12.70M
YoY Change -0.72% -41.36% -16.07%
Net Earnings / Revenue
Basic Earnings Per Share $2.51 $12.03
Diluted Earnings Per Share $2.51 -$2.786M $12.03
COMMON SHARES
Basic Shares Outstanding 5.015M 1.258M
Diluted Shares Outstanding 5.015M 1.258M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.21M $5.795M $5.795M
YoY Change 490.4% -66.66%
Cash & Equivalents $34.21M $5.800M $5.795M
Short-Term Investments
Other Short-Term Assets $1.290M $806.3K $806.3K
YoY Change 60.02% 63.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.50M $6.729M $6.729M
YoY Change 427.65% -62.36%
LONG-TERM ASSETS
Property, Plant & Equipment $20.45K $22.21K $22.21K
YoY Change -7.92% 2.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.44K $22.21K $22.21K
YoY Change -7.97% 2.49%
TOTAL ASSETS
Total Short-Term Assets $35.50M $6.729M $6.729M
Total Long-Term Assets $20.44K $22.21K $22.21K
Total Assets $35.52M $6.751M $6.751M
YoY Change 426.21% -62.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.297M $1.260M $1.260M
YoY Change 2.87% 205.11%
Accrued Expenses $698.4K $352.2K $352.2K
YoY Change 98.33% 433.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.995M $1.612M $1.612M
YoY Change 23.72% 236.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.995M $1.612M $1.612M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.995M $1.612M $1.612M
YoY Change 23.72% 236.59%
SHAREHOLDERS EQUITY
Retained Earnings -$1.530M
YoY Change
Common Stock $126.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.53M $5.139M $5.139M
YoY Change
Total Liabilities & Shareholders Equity $35.52M $6.751M $6.751M
YoY Change 426.21% -62.28%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$12.61M -$1.530M -$12.70M
YoY Change -0.72% -41.36% -16.07%
Depreciation, Depletion And Amortization $4.966K $1.230K $4.872K
YoY Change 1.93% 10.98%
Cash From Operating Activities -$8.711M -$1.206M -$8.102M
YoY Change 7.51% -20.68% -31.84%
INVESTING ACTIVITIES
Capital Expenditures $3.199K $0.00 $5.413K
YoY Change -40.9% -203.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.199K $0.00 -$5.413K
YoY Change -40.9% 3.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.13M -20.00M -3.479M
YoY Change -1167.29% -928.69%
NET CHANGE
Cash From Operating Activities -8.711M -1.206M -8.102M
Cash From Investing Activities -3.199K 0.000 -5.413K
Cash From Financing Activities 37.13M -20.00M -3.479M
Net Change In Cash 28.42M -21.20M -11.59M
YoY Change -345.27% 1295.05% 1.0%
FREE CASH FLOW
Cash From Operating Activities -$8.711M -$1.206M -$8.102M
Capital Expenditures $3.199K $0.00 $5.413K
Free Cash Flow -$8.714M -$1.206M -$8.108M
YoY Change 7.48% -20.68% -31.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
12.03
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5015100
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1257579
CY2021 dei Entity Registrant Name
EntityRegistrantName
Synaptogenix, Inc.
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001571934
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6730180
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257579
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
333-249434
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1585656
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6728789
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20445
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22212
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
698406
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
352154
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1994912
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei City Area Code
CityAreaCode
973
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1612489
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257579
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
674
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
126
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par valueper share
CY2021 dei Trading Symbol
TradingSymbol
SNPX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Assets
Assets
35524660
CY2020Q4 us-gaap Assets
Assets
6751001
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1296506
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1260335
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
59482160
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6809647
CY2021 dei Auditor Name
AuditorName
Friedman LLP
CY2021 dei Auditor Location
AuditorLocation
East Hanover, NJ
CY2021 dei Auditor Firm
AuditorFirmId
711
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34213989
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5795055
CY2021Q4 snpx Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
1271537
CY2020Q4 snpx Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
781798
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18689
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
151936
CY2021Q4 us-gaap Assets Current
AssetsCurrent
35504215
CY2021 dei Local Phone Number
LocalPhoneNumber
242-0005
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6730180
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47670744
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6668859
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14141670
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1530473
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33529748
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5138512
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35524660
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6751001
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4336414
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3069034
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8281893
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8087376
CY2021 us-gaap Operating Expenses
OperatingExpenses
12618307
CY2020 us-gaap Operating Expenses
OperatingExpenses
11156410
CY2020 snpx Warrant Amendment Expense
WarrantAmendmentExpense
1700000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
7110
CY2020 us-gaap Interest Income Other
InterestIncomeOther
153213
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7110
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1546787
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12611197
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12703197
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-12611197
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12703197
CY2020 snpx Deemed Dividend As Result Of Common Stock And Warrants Issued Pursuant To Spin Off
DeemedDividendAsResultOfCommonStockAndWarrantsIssuedPursuantToSpinOff
2427000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12611197
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15130197
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.51
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
12.03
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5015100
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1257579
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
17418765
snpx Net Change In Investment
NetChangeInInvestment
16524189
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1701376
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
120000
snpx Warrants Issued During Period Value Issued For Services
WarrantsIssuedDuringPeriodValueIssuedForServices
380740
snpx Warrant Amendment Expense
WarrantAmendmentExpense
1700000
us-gaap Net Income Loss
NetIncomeLoss
-11172724
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26672346
CY2020Q4 snpx Decrease In Equity Pursuant To Merger
DecreaseInEquityPursuantToMerger
20003361
CY2020Q4 snpx Amount Of Increase Or Decrease In Equity Due To Spin Off
AmountOfIncreaseOrDecreaseInEquityDueToSpinOff
0
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-1530473
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5138512
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5138512
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
1529
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3282384
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
560033
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
27159
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23784160
CY2021 snpx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
13350226
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-12611197
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33529748
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-12611197
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12703197
CY2020 snpx Parent Company Employee Benefits And Share Based Compensation
ParentCompanyEmployeeBenefitsAndShareBasedCompensation
1701376
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3282384
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
27159
CY2021 snpx Issuance Of Stock And Warrants For Services
IssuanceOfStockAndWarrantsForServices
560033
CY2020 snpx Consulting Services Paid By Issuance Of Parent Company Common Stock
ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock
120000
CY2020 snpx Consulting Services Paid By Issuance Of Parent Company Common Stock Warrants
ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants
380740
CY2020 snpx Warrant Amendment Expense
WarrantAmendmentExpense
1700000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4966
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4872
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
356492
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
439622
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
36172
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
847254
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
346250
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
286179
CY2021 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3900472
CY2020 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
4600799
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8710725
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8102398
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3199
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5413
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3199
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5413
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23784161
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13350226
CY2021 snpx Payments In Lieu Shares For Reverse Stock Split
PaymentsInLieuSharesForReverseStockSplit
1529
CY2020 snpx Net Transfer From To Parent
NetTransferFromToParent
16524189
CY2020 snpx Distribution Pursuant To Merger
DistributionPursuantToMerger
20003361
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37132858
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3479172
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
28418934
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11586983
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5795055
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17382038
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34213989
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5795055
CY2020 snpx Deemed Dividend As Result Of Common Stock And Warrants Issued Pursuant To Spin Off
DeemedDividendAsResultOfCommonStockAndWarrantsIssuedPursuantToSpinOff
2427000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and we operate independently from Neurotrope. On December 7, 2020 we became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) as the Company amended and restated their certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. Our shares of common stock are listed on The Nasdaq Capital Market under the symbol “SNPX.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neurotrope Bioscience, Inc. was incorporated in Delaware on October 31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). The Company is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 4 - Related Party Transactions and Licensing / Research Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties’ various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Spin-Off</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2020, Neurotrope,and Petros Pharmaceuticals, Inc., a Delaware corporation (“Petros”) and formerly Metuchen Pharmaceuticals LLC, consummated their reverse merger transactions (the “Mergers”) contemplated by a certain Agreement and Plan of Merger dated as of May 17, 2020 (the “Merger Agreement”), as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a condition to the Mergers, Neurotrope approved a transaction (the “Spin-Off”), which became effective on December 7, 2020, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience, Inc., and (ii) holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants that were not amended and restated as of the Spin-Off Record Date received a pro rata distribution at the rate of (i) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock held, (ii) one share of Synaptogenix common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii) one share of Synaptogenix, Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the “Distribution”). Any fractional shares were paid in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of Neurotrope’s amended and restated warrants to purchase 4,889,158 shares of Neurotrope common stock (the “A&amp;R Warrants”) received 977,831 warrants to purchase shares of Synaptogenix common stock upon the exercise of such A&amp;R Warrants held as of the Spin-Off Record Date (collectively, the “Spin-Off Warrants”). All the warrants have five year terms from December 2, 2020. See Note 8 – Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Liquidity Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had approximately $34.2 million in cash and cash equivalents as compared to $5.8 million at December 31, 2020. The Company expects that its current cash and cash equivalents, approximately $32.3 million as of the date of this annual report, which includes cash received during January and February, 2022 of approximately $0.6 million from the exercise of investor warrants, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plans for Bryostatin-1, our novel drug candidate targeting the activation of PKC epsilon and other development projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the current Phase 2 trial. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Other Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize Bryostatin-1 for the treatment of AD. In June 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to be the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic bryostatin. See Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company’s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our current Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34200000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5800000
CY2021Q4 snpx Cash And Cash Equivalents Expected Amount At Financial Reporting Date
CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate
32300000
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
79100000
CY2020Q4 snpx Class Of Warrant Or Right Numerator Used To Determine Initial Exercise Price Of Spin Off Warrants
ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
2430000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-line:none;">Use of Estimates:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
6500000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27700000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
50000
CY2020Q4 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2021Q4 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2020Q4 snpx Issue Of Shares On Spin Off
IssueOfSharesOnSpinOff
1257579
CY2020Q4 snpx Spin Off Ratio
SpinOffRatio
0.20
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16600000
CY2021Q4 us-gaap Grants Receivable
GrantsReceivable
1100000
CY2020Q4 us-gaap Grants Receivable
GrantsReceivable
850000
CY2017Q1 snpx Annual License Maintenance Fee
AnnualLicenseMaintenanceFee
10000
CY2017Q1 snpx Commitment To Pay Fees
CommitmentToPayFees
2100000
CY2020 snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
CY2021 snpx Number Of Statements Entered Into Agreement
NumberOfStatementsEnteredIntoAgreement
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 snpx Number Of Votes Per Share Owned
NumberOfVotesPerShareOwned
1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
250000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
625000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
123850
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.84
CY2021 snpx Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
123850
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.84
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
64463
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.84
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1000000.0
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y1M24D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1021319
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
978077
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1700000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
978077
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
52983
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
978077
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
6919051
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1631603
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
6265525
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
83334
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.49
CY2021 snpx Warrants And Rights Outstanding Remaining Term
WarrantsAndRightsOutstandingRemainingTerm
P3Y6M
CY2021Q4 snpx Intrinsic Value Of Warrants
IntrinsicValueOfWarrants
5000000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13350000
snpx Parent Company Employee Benefits And Share Based Compensation
ParentCompanyEmployeeBenefitsAndShareBasedCompensation
1701376
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
500740
snpx Contributions From Parent
ContributionsFromParent
16524189
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1700000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
20426305

Files In Submission

Name View Source Status
0001410578-22-000610-index-headers.html Edgar Link pending
0001410578-22-000610-index.html Edgar Link pending
0001410578-22-000610.txt Edgar Link pending
0001410578-22-000610-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snpx-20211231.xsd Edgar Link pending
snpx-20211231x10k.htm Edgar Link pending
snpx-20211231x10k001.jpg Edgar Link pending
snpx-20211231x10k004.jpg Edgar Link pending
snpx-20211231x10k005.jpg Edgar Link pending
snpx-20211231x10k007.jpg Edgar Link pending
snpx-20211231x10k_htm.xml Edgar Link completed
snpx-20211231xex23d1.htm Edgar Link pending
snpx-20211231xex31d1.htm Edgar Link pending
snpx-20211231xex31d2.htm Edgar Link pending
snpx-20211231xex32d1.htm Edgar Link pending
snpx-20211231_cal.xml Edgar Link unprocessable
snpx-20211231_def.xml Edgar Link unprocessable
snpx-20211231_lab.xml Edgar Link unprocessable
snpx-20211231_pre.xml Edgar Link unprocessable